# A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery

> **NCT04829916** · PHASE1 · COMPLETED · sponsor: **Guard Therapeutics AB** · enrollment: 13 (actual)

## Conditions studied

- Acute Kidney Injury (AKI)

## Interventions

- **DRUG:** RMC-035
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04829916
- **Lead sponsor:** Guard Therapeutics AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-16
- **Primary completion:** 2021-07-15
- **Final completion:** 2021-07-15
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04829916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04829916, "A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04829916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*